Tejal Somvanshi

Tejal Somvanshi

Ozempic-Linked Drug Semaglutide Trial Shows 52% Drop in Kidney Disease Markers – Is This the Next Big Breakthrough for CKD Patients?

Popular diabetes drug Ozempic shows surprising 52% drop in kidney disease markers among non-diabetic patients - how will this reshape CKD treatment?

Photo Source: Google

Photo Source: Google

Photo Source: Google

Photo Source: Google

Research team's 24-week trial demonstrates Ozempic slashed urinary protein levels while reducing inflammation by 30% in CKD patients.

Participants experienced a remarkable 33% improvement in heart failure indicators alongside a 10% average weight reduction.

Photo Source: Google

Photo Source: Google

Photo Source: Google

Photo Source: Google

International study shows blood pressure improvements matching traditional medications' effectiveness - without the usual side effects.

Even after treatment ended, kidney health markers remained significantly improved, suggesting lasting benefits for patients.

Photo Source: Google

Photo Source: Google

Photo Source: Google

Photo Source: Google

Dr. Heerspink's team observed both direct anti-inflammatory effects and indirect benefits through weight loss in kidney tissues.

Can Ozempic potentially reduce future dialysis needs and kidney transplants? Scientists are eager to investigate.

Photo Source: Google

Photo Source: Google

Photo Source: Google

Photo Source: Google

Study focused exclusively on non-diabetic patients with specific kidney function levels and BMI requirements.

Despite supply shortages limiting broader research, initial results position Ozempic as a promising option for CKD patients managing obesity.

Photo Source: Google

Photo Source: Google

Next Story

Next Story

Lead-Contaminated Turmeric From South Asia: 1000 Micrograms Per Gramβ€”A Silent Global Health Crisis

Learn more